• Certified Lab Equipment & Reagents
  • Fast Dispatch on In-Stock Items
  • Expert Scientific Support

Product details

PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2744), CF640R conjugate, 0.1mg/mL

Catalog number BNC402744-500

Price for BNC402744-500

Sign In for Pricing

Size / count 1x 500 µL

About this product

Engagement of CD28 by B7-1 (CD80) or B7-2 (CD86) in the presence of antigen promotes T-cell proliferation, cytokine production, differentiation of effector T-cells and the induction of BCLX, a promoter of T-cell survival. Engagement of CTLA4 by B7-1 or B7-2, on the other hand, may inhibit proliferation and interleukin-2 (IL-2) production. PD-L1 is 290-amino acid type I transmembrane protein, which is 20% and 15% identical to B7-1 and B7-2, respectively, has immunoglobulin V-like and C-like domains and a 30-amino acid cytoplasmic tail. PD-L1 does not bind CD28, cytotoxic T-lymphocyte A4 or ICOS (inducible co-stimulator) . IL-2, although produced in small amounts, is required for the effect of PD-L1 co-stimulation. PD-L2 protein contains a signal sequence, IgV- and IgC-like domains, a transmembrane region and a cytoplasmic region. The constitutive expression of PD-L1 and PD-L2 on parenchymal cells of heart, lung and kidney suggests that the PD-1-PD-L system could provide unique negative signaling to help prevent autoimmune diseases. Primary antibodies are available purified, or with a selection of fluorescent CF® Dyes and other labels. CF® Dyes offer exceptional brightness and photostability. Note: Conjugates of blue fluorescent dyes like CF®405S and CF®405M are not recommended for detecting low abundance targets, because blue dyes have lower fluorescence and can give higher non-specific background than other dye colors.

Specifications

Catalog number
BNC402744-500
Size / count
1x 500 µL
Dry ice
No
Hazardous
No
Discontinued
No
CAS Number
9007-83-4
Synonyms
B7 homolog 1; B7-H1; CD274; PD-L1; PDCD1 ligand 1; PDCD1L1; PDCD1LG1; Programmed cell death 1 ligand 1
UNSPSC
41116161
UNSPSC Description
Primary and secondary antibodies for multiple methodology immunostaining detection application
Gene Name
CD274
Gene ID
29126
NCBI Gene ID
521989
UniProt
Q9NZQ7
Swiss Prot
Q9NZQ7
Host
Mouse
Species Reactivity
Human, Mouse
Reactivity
B7-H1|CD274|PD-L1|PDCD1LG1
Immunogen
Recombinant fragment of human CD274 protein (around aa39-191) (exact sequence is proprietary)
Target Antigen
B7-H1 | CD274 | PD-L1 | PDCD1LG1
Clonality
Monoclonal
Clone
PDL1/2744
Type
Primary
Source
Animal
Origin
Animal
Applications
WB (verified)
Positive Control
Jurkat, HEK293 or HepG2 cells. Lung SqCC, Cervical or Breast Carcinoma.
Stability
2 years
Concentration
0.1 mg/mL
Buffer
PBS, 0.1% BSA, 0.05% azide
Molecular Weight
37-50 kDa
Shipping Conditions
RT (ND)
Storage Conditions
Stable at room temperature or 37°C (98°F) for 7 days.
Notes
Protect from light
Shelf Life
Guaranteed for at least 24 months from date of receipt when stored as recommended
Fragment
IgG1, kappa
Species
Mus musculus (mouse), BSA from bovine serum (Bos taurus) or recombinant BSA produced in Chinese hamster ovary cells.
Classification
0.05% sodium azide (CAS 26628-22-8)
Conjugate
CF640R

Frequently Asked Questions

What is the catalog number for PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2744), CF640R conjugate, 0.1mg/mL?

The catalog number for PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2744), CF640R conjugate, 0.1mg/mL is BNC402744-500.

What sizes are available for PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2744), CF640R conjugate, 0.1mg/mL?

PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2744), CF640R conjugate, 0.1mg/mL is available in the following size(s): 1x 500 µL.

Is PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2744), CF640R conjugate, 0.1mg/mL in stock?

PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2744), CF640R conjugate, 0.1mg/mL is currently made to order / not held in immediate stock. Contact us for lead time.

Who manufactures PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2744), CF640R conjugate, 0.1mg/mL?

PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2744), CF640R conjugate, 0.1mg/mL is manufactured by Biotium.

What is the estimated delivery time for PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2744), CF640R conjugate, 0.1mg/mL?

Estimated delivery time for PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2744), CF640R conjugate, 0.1mg/mL is approximately 15 business day(s), depending on your location.

Where can I find the safety data sheet (SDS/MSDS) for PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2744), CF640R conjugate, 0.1mg/mL?

The safety data sheet for PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2744), CF640R conjugate, 0.1mg/mL is available here: https://biotium.com/wp-content/uploads/2018/06/SDS-primary-antibodies.pdf.

What is PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2744), CF640R conjugate, 0.1mg/mL used for?

Engagement of CD28 by B7-1 (CD80) or B7-2 (CD86) in the presence of antigen promotes T-cell proliferation, cytokine production, differentiation of effector T-cells and the induction of BCLX, a promoter of T-cell survival. Engagement of CTLA4 by B7-1 or B7-2, on the other hand, may inhibit proliferat

What should I do if I need to report a performance issue with a specific lot of this product?

Provide the catalogue number, product name, lot number, and your experimental results to our technical support team. They’ll investigate and, if needed, escalate to the manufacturer, provided the product was used before expiry and stored correctly.

What is the isotype of this antibody?

Isotype information such as IgG1 or IgG2a is listed in the product specifications on the datasheet, relevant for selecting compatible detection reagents.

Can I get a trial-size or discounted first order of this product?

We don’t generally offer free samples, but trial discounts in exchange for feedback and validation results are almost always possible. Contact us with your intended application to arrange one.

You Might Also Like
CD3e (CRIS-7), CF647 conjugate, 0.1mg/mL
CD3e (CRIS-7), CF647 conjugate, 0.1mg/mL
By Afraxis
Sign In for Pricing
Ref: BNC471050-100
Cytokeratin 8/18 (C-51), CF568 conjugate, 0.1mg/mL
Cytokeratin 8/18 (C-51), CF568 conjugate, 0.1mg/mL
By Afraxis
Sign In for Pricing
Ref: BNC680034-500
Major Vault Protein (MVP) (1032), CF488A conjugate, 0.1mg/mL
Major Vault Protein (MVP) (1032), CF488A conjugate, 0.1mg/mL
By Afraxis
Sign In for Pricing
Ref: BNC880225-500
Complement C4d (C4D204), CF568 conjugate, 0.1mg/mL
Complement C4d (C4D204), CF568 conjugate, 0.1mg/mL
By Afraxis
Sign In for Pricing
Ref: BNC680204-100
P27 / KIP1 (SX53G8), CF405S conjugate, 0.1mg/mL
P27 / KIP1 (SX53G8), CF405S conjugate, 0.1mg/mL
By Afraxis
Sign In for Pricing
Ref: BNC040669-500
CD71 (66IG10), CF647 conjugate, 0.1mg/mL
CD71 (66IG10), CF647 conjugate, 0.1mg/mL
By Afraxis
Sign In for Pricing
Ref: BNC470871-500
Cytokeratin, LMW (AE-1), CF647 conjugate, 0.1mg/mL
Cytokeratin, LMW (AE-1), CF647 conjugate, 0.1mg/mL
By Afraxis
Sign In for Pricing
Ref: BNC470253-500
CD47 (B6H12.2), CF740 conjugate, 0.1mg/mL
CD47 (B6H12.2), CF740 conjugate, 0.1mg/mL
By Afraxis
Sign In for Pricing
Ref: BNC740437-100